MARKET

TRVN

TRVN

Trevena
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.570
+0.230
+9.83%
After Hours: 2.520 -0.05 -1.95% 16:51 11/27 EST
OPEN
2.330
PREV CLOSE
2.340
HIGH
2.580
LOW
2.324
VOLUME
3.37M
TURNOVER
--
52 WEEK HIGH
3.680
52 WEEK LOW
0.4600
MARKET CAP
403.57M
P/E (TTM)
-11.5092
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Trevena Highlights Publication Of Gastrointestinal Tolerability Profile Of Its OLINVYK Injection In Pain And Therapy
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication, titled
Benzinga · 11/20 12:06
Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK (oliceridine) injection in Pain and Therapy
\-- OLINVYK significantly reduced risk of vomiting and rescue antiemetic use compared to IV morphine in a retrospective analysis\--CHESTERBROOK, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication, titled “Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials,” with lead author Tim Beard, M.D., Chair of the Department of Surgery at Summit Medical Group (DOI: https://doi.org/10.1007/s40122-020-00216-x).The results of this analysis highlight an improved gastrointestinal (GI) tolerability profile, with OLINVYK demonstrating a ~2-3x likelihood of achieving a “complete GI response” compared to IV morphine under equianalgesic conditions. A complete GI response is defined as the proportion of patients who complete the study without vomiting and without using any antiemetics.“There are multiple types of procedures where post-operative nausea or vomiting can disrupt the integrity of a surgery, posing a significant challenge to a patient’s recovery,” said Tim Beard, M.D. “Based on the results of this analysis, OLINVYK has the potential to greatly reduce the risk of nausea and vomiting following surgery, compared to IV morphine. These are compelling findings that suggest the clinical advantages OLINVYK may offer in the post-operative acute care setting.”Publication Key Points: * Orthopedic surgery-bunionectomy study: A higher proportion of patients achieved ‘complete GI response’ with all OLINVYK treatment regimens (0.1 mg: 76.3%; 0.35 mg: 53.2%; 0.5 mg: 49.4%) compared to IV morphine (32.9%; p < 0.05 for all 3 OLINVYK dose regimens). * Plastic surgery-abdominoplasty study: A higher proportion of patients achieved ‘complete GI response’ with all OLINVYK treatment regimens (0.1 mg: 59.7%; 0.35 mg: 39.2%; 0.5 mg: 29.9%) compared to IV morphine (28.8%; p ≤ 0.0001 for OLINVYK 0.1 mg). * Pooled data from both trials: There was a statistically significantly higher rate of ‘complete GI response’ associated with OLINVYK 0.1 mg (68%) and 0.35 mg (46.2%) compared to IV morphine (30.8%; p ≤ 0.005). * Under equianalgesic conditions: Where analgesia as measured by Sum of Pain Intensity Difference (SPID) scores was held constant, patients were 3.1x more likely to achieve a ‘complete GI response’ with OLINVYK than IV morphine in the orthopedic surgery-bunionectomy study (95% CI: 1.78, 5.56; p <0.0001), and 1.9x more likely in the plastic-surgery abdominoplasty study (95% CI: 1.09, 3.36; p = 0.024).About OLINVYK™ (oliceridine) injectionOLINVYK is a new chemical entity approved by the FDA in August 2020. OLINVYK contains oliceridine, a Schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg/1 mL and 2 mg/2 mL single-dose vials, and a 30 mg/30 mL single-patient-use vial for patient-controlled analgesia (PCA). Approved PCA doses are 0.35 mg and 0.5 mg and single bolus doses greater than 3 mg have not been evaluated. The cumulative daily dose should not exceed 27 mg. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information at www.OLINVYK.com.About TrevenaTrevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.For more information, please visit www.Trevena.com Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “objective,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “ongoing,” or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.For more information, please contact:Investor Contact:Dan Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com (617) 430-7576Company Contact:Bob Yoder SVP and Chief Business Officer Trevena, Inc. (610) 354-8840
GlobeNewswire · 11/20 12:00
Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting
&#92;-- Live presentation highlighting TRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clottingPosters on OLINVYK benefit-risk profile and TRV250 Phase 1 pharmacokinetics &#92;--CHESTERBROOK, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq
GlobeNewswire · 09/21 11:00
Is the Options Market Predicting a Spike in Trevena (TRVN) Stock?
Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.
Zacks · 09/18 13:20
Benzinga's Top Upgrades, Downgrades For September 14, 2020
Upgrades * For Amkor Technology Inc (NASDAQ: AMKR), Credit Suisse upgraded the previous rating of Neutral to the current rating Outperform. For the second quarter, Amkor Technology had an EPS of $0.23, compared to year-ago quarter EPS of $0.01. The current stock performance of Amkor Technology shows
Benzinga · 09/14 15:33
Is Trevena Stock a Buy Right Now? This Is What You Need to Know
Shares of drug maker Trevena (TRVN) are up by 112% in 2020. Behind the rally lies the FDA’s approval of Olinvyk (oliceridine), the company’s opioid agonist. The treatment has been given the go ahead for the management of acute pain in adults who require an intravenous opioid pain reliever.However, the
TipRanks · 09/03 22:20
Trevena, Inc. to Present at September Virtual Investor Conferences
\- H.C. Wainwright: 22nd Annual Global Investment Conference - September 14th\- Cantor Fitzgerald Virtual Global Healthcare Conference - September 17th-Oppenheimer Fall Healthcare Life Sciences & MedTech Summit - September 23rdCHESTERBROOK, Pa., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Trevena,
GlobeNewswire · 09/02 12:00
Trevena: Strong Buy After Opioid Approval And Potential Supplementary COVID-19 Value
OLINVYK is awaiting controlled substance scheduling from the DEA but is expected to be commercially available by 2021.TRV027 is targeting AT1 receptors and looks to prevent coagulopathy, lung damage, ARDS and other lung/blood clot-related complications from Covid-19.Initial core market is expected to be ~$1.5 billion on a 9 million base patient assumption, but expanded market could be ~$4.5 billion.OLINVYK has a superior safety and tolerability profile to IV morphine, as well as rapid onset of pain relief and ease of use.
Seekingalpha · 08/31 09:55
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TRVN. Analyze the recent business situations of Trevena through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TRVN stock price target is 5.25 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 92
Institutional Holdings: 18.77M
% Owned: 11.95%
Shares Outstanding: 157.03M
TypeInstitutionsShares
Increased
21
3.51M
New
29
-415.97K
Decreased
17
4.54M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Leon Moulder
President/Chief Executive Officer/Director
Carrie Bourdow
Chief Financial Officer/Senior Vice President
Barry Shin
Senior Vice President/Chief Compliance Officer
Scott Applebaum
Senior Vice President
Mark Demitrack
Senior Vice President
Robert Yoder
Director
Maxine Gowen
Independent Director
Scott Braunstein
Independent Director
Michael Dougherty
Independent Director
Julie McHugh
Independent Director
Jake Nunn
Independent Director
Anne Phillips
Independent Director
Barbara Yanni
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TRVN
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Trevena Inc stock information, including NASDAQ:TRVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRVN stock methods without spending real money on the virtual paper trading platform.